Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Korro Bio (KRRO) Short term Debt (2021 - 2023)

Historic Short term Debt for Korro Bio (KRRO) over the last 3 years, with Q1 2023 value amounting to $11.7 million.

  • Korro Bio's Short term Debt rose 25004.5% to $11.7 million in Q1 2023 from the same period last year, while for Mar 2023 it was $11.7 million, marking a year-over-year increase of 25004.5%. This contributed to the annual value of $10.0 million for FY2022, which is 110048.02% up from last year.
  • Per Korro Bio's latest filing, its Short term Debt stood at $11.7 million for Q1 2023, which was up 25004.5% from $10.0 million recorded in Q4 2022.
  • Korro Bio's Short term Debt's 5-year high stood at $11.7 million during Q1 2023, with a 5-year trough of $833000.0 in Q4 2021.
  • Its 3-year average for Short term Debt is $6.7 million, with a median of $7.1 million in 2022.
  • As far as peak fluctuations go, Korro Bio's Short term Debt surged by 110048.02% in 2022, and later surged by 25004.5% in 2023.
  • Korro Bio's Short term Debt (Quarter) stood at $833000.0 in 2021, then soared by 1100.48% to $10.0 million in 2022, then grew by 16.67% to $11.7 million in 2023.
  • Its Short term Debt stands at $11.7 million for Q1 2023, versus $10.0 million for Q4 2022 and $8.3 million for Q3 2022.